Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533136) titled 'Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax' on April 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Walter Reed Army Institute of Research (WRAIR)

Condition: Uncomplicated P. Vivax Mono-infection

Intervention: Drug: Tafenoquine (TQ) Drug: Chloroquine (CQ) Drug: Dihydroartemisinin-piperaquine (DHA-PPQ)

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: May 1, 2026

Target Sample Size: 300

Countries of Recruitment:...